Pricing Log in Create free account
Friday 6 November 2026 Export ROIV’s income statement to Excel — free account

Roivant Sciences Ltd.

ROIV Healthcare Biotechnology

Roivant Sciences Ltd.’s revenue for fiscal 2026 (year ended March 2026) was $8.3 million, down 71.6% from fiscal 2025.

Revenue
−33.6%
EPS
+21.2%
Free cash flow
−30.0%

Quarter to June 2026, against a year earlier

38.90 2.28 +6.23%
Market cap
$26.5B
P/E
0.0×
Fwd P/E
−27.7×
Dividend yield
—
F-score
2/9
Altman Z
28.31
Beneish M
n/a
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Roivant Sciences Ltd. (ROIV) EV/Sales

Alert me on EV/Sales

As of 6 November 2026, Roivant Sciences Ltd. (ROIV) trades at a EV/Sales of 3,255×. Over the past ten years it has ranged from 0.0× (March 2021) to 3,534× (September 2026); the current reading is higher than 99% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.6×.

EV/Sales, daily

Embed this chart

Annual newest first

Period EV/Sales Change
FY2026 1,874× 1,875.69%
FY2025 94.9× 123.41%
FY2024 42.5× (34.94%)
FY2023 65.3× 147.43%
FY2022 26.4× (85.05%)
FY2021 176× —

Quarterly newest first

Period EV/Sales Change
Jun 2026 2,920× 55.77%
Mar 2026 1,874× 128.53%
Dec 2025 820× 167.15%
Sep 2025 307× 104.51%
21 more quarters

Against its own ten years

Low 0.0× High 3,534×
Ten-year median 95.0×
Current reading's percentile 99

EV/Sales against peers

Company EV/Sales
BNTX BioNTech SE Sponsored ADR compare 1.9×
INCY Incyte Corporation compare 3.4×
ALNY Alnylam Pharmaceuticals, Inc. compare 3.7×
ONC BeOne Medicines Ltd. - Sponsored ADR compare 6.2×
GMAB Genmab A/S Sponsored ADR compare 8.8×
RPRX Royalty Pharma PLC compare 14.5×
INSM Insmed, Inc. compare 16.2×
RVMD Revolution Medicines, Inc. compare 185×
ROIV Roivant Sciences Ltd. 3,255×
Biotechnology industry median 9.0×
Healthcare sector median 3.6×
Market median 2.1×

What EV/Sales is

EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)

The full definition of EV/Sales →

More on ROIV